Healthcare Professionals
-
Clinical News
NEW HOPE FOR THALASSAEMIA/SCD | UK Trial Of Lab Grown Red Blood Cells Begins
The Restore trial, led jointly by NHS Blood and Transplant and the University of Bristol, is studying the lifespan of the lab grown cells compared with infusions of standard red blood…
أكمل القراءة » -
TIF News (AR)
TIF Presents Its Newly Launched SCD Educational Course for Healthcare Professionals On 9 April
TIF is delighted to announce the organisation of a Virtual Presentation Event of the ‘TIF Sickle Cell Disease Educational Course for Healthcare Professionals’ – an online course providing comprehensive information…
أكمل القراءة » -
Clinical News
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
أكمل القراءة » -
أخبار
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
أكمل القراءة » -
TIF News (AR)
TIF European Thalassaemia & Sickle Cell Disease Symposium To Take Place On 11-13 December 2020
TIF is proudly organising the European Thalassaemia & Sickle Cell Disease Symposium, a joint patients’ and healthcare professionals’ three-day educational event which will take place online on 11 – 13 December…
أكمل القراءة » -
أخبار
Virtual Conference on Alpha Thalassaemia Major By UCSF on 8-9 January 2021
The Center for Maternal-Fetal Precision Medicine (UCSF) will host a 2-day online international conference on Alpha Thalassaemia Major, which was once considered universally fatal in utero, on 8-9 January 2021. …
أكمل القراءة » -
TIF News (AR)
PK Deficiency Resources Now Available On TIF’s Website
Recognizing the similarities of thalassaemia with other rare anaemias, particularly those affecting red blood cells, (e.g. PKD, SCD), and noting the absence of disease-specific united internationally coordinated patient organizations to…
أكمل القراءة » -
Clinical News
What’s New In Clinical Trials for Thalassaemia and Sickle Cell Disease?
There is a lot of hustle and bustle in the scientific fields of thalassemia and sickle cell disease during the past few months, with many companies making remarkable progress in…
أكمل القراءة » -
Clinical News
EU Approves Adakveo to Treat Vaso Occlusive Crises in Sickle Cell Disease Patients
The European Commission has approved Novartis’ Adakveo (crizanlizumab) as a preventive treatment for recurrent Vaso-Occlusive Crises (VOCs) in patients, 16 and older, with sickle cell disease (SCD). This approval follows a recommendation for conditional approval issued in July…
أكمل القراءة » -
eThalED Webinars
eThalED COURSE: Current Care & New Advances in Iron Chelation by Dr. Farrukh Shah
TIF´s last webinar for the eThalED series for Medical Specialists on October 16, 2020, featured Dr Farrukh Shah, Consultant Haematologist, Whittington Hospital, London, UK, who reviewed all the current practices…
أكمل القراءة »